Cerevance is a revolutionary pharmaceutical company using the proprietary NETSseq platform to develop novel symptomatic and disease modifying therapies for CNS disorders

Leveraging a vast and expanding collection of over 16,000 human brain tissue samples, Cerevance is uncovering subtle molecular changes that contribute to disease progression, providing a potentially …

Learn how Cerevance is impacting CNS research around the world and find ways to participate their discovery process.

Cerevance is currently conducting a global Phase 3 clinical study (”ARISE”) to evaluate solengepras as an adjunctive treatment in patients with Parkinson’s disease with motor fluctuations

Apr 1, 2025 · Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders.

Cerevance is a private pharmaceutical company whose lead program, CVN424, a first-in-class compound acting on a novel target, recently demonstrated significant and meaningful efficacy in a …

CVN424, Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), demonstrated significant and clinically meaningful efficacy in a 135-patient …

About Cerevance Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative diseases and obesity.

Cerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's …

Virtual Scheduled Meetings Learn More October 10, 2023 Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum. Company management will host one-on-one meetings …